Supplementary Data. Correlation analysis. Importance of normalizing indices before applying SPCA

Size: px
Start display at page:

Download "Supplementary Data. Correlation analysis. Importance of normalizing indices before applying SPCA"

Transcription

1 Supplementary Data Correlation analysis The correlation matrix R of the m = 25 GV indices calculated for each dataset is reported below (Tables S1 S3). R is an m m symmetric matrix, whose entries r ij = r ji represent the correlation among the i-th and j-th elements of the vector collecting all GV indices; the diagonal entries of the correlation matrix R are equal to 1, quantifying the correlation between a GV index and itself. Results obtained in the three cases are consistent with the correlation values documented in the literature Importance of normalizing indices before applying SPCA Normalizing GV indices before applying SPCA is key to avoiding the possibility that the heterogeneity of their scale (e.g.,,, and have numerical values larger than,, and Hypoglycemic Index) may influence the results. For instance, without normalization, results of SPCA would change when glucose concentration is measured in mmol/l (Table S4, right columns) rather than in mg/ dl (Table S4, left columns), simply because some indices (such as,,, and ) decrease their values by 18 times when converting from mg/l to mmol/l.

2 Supplementary Table S1. Dataset 1 (17 Continuous Glucose Monitoring Time-Series) w dm w dm M , Average Daily Risk Range;, Blood Glucose Risk Index;, percentage coefficient of variation;, Glycemic Risk Assessment Diabetes Equation;,, and, percentages of score due to euglycemia, hypoglycemia, and hyperglycemia, respectively;, High Blood Glucose Index;, Hyperglycemic Index;, Hypoglycemic Index;, Index of Glucose Control;, Interquartile Range;, Low Blood Glucose Index;, Mean Amplitude of Glycemic Excursions; dm, of daily s; w, of daily s (within-day variability);,, and, percentage of values in target, below target, and above target, respectively.

3 Supplementary Table S2. Dataset 2 (16 Continuous Glucose Monitoring Time-Series) w dm w dm M , Average Daily Risk Range;, Blood Glucose Risk Index;, percentage coefficient of variation;, Glycemic Risk Assessment Diabetes Equation;,, and, percentages of score due to euglycemia, hypoglycemia, and hyperglycemia, respectively;, High Blood Glucose Index;, Hyperglycemic Index;, Hypoglycemic Index;, Index of Glucose Control;, Interquartile Range;, Low Blood Glucose Index;, Mean Amplitude of Glycemic Excursions; dm, of daily s; w, of daily s (within-day variability);,, and, percentage of values in target, below target, and above target, respectively.

4 Supplementary Table S3. Dataset (33 Continuous Glucose Monitoring Time-Series) w dm w dm J - index M , Average Daily Risk Range;, Blood Glucose Risk Index;, percentage coefficient of variation;, Glycemic Risk Assessment Diabetes Equation;,, and, percentages of score due to euglycemia, hypoglycemia, and hyperglycemia, respectively;, High Blood Glucose Index;, Hyperglycemic Index;, Hypoglycemic Index;, Index of Glucose Control;, Interquartile Range;, Low Blood Glucose Index;, Mean Amplitude of Glycemic Excursions; dm, of daily s; w, of daily s (within-day variability);,, and, percentages of values in target, below target, and above target, respectively.

5 Supplementary Table S4. Example of How the Lack of Indices Normalization Can Lead to Inconsistencies in the Results Dataset, PC 1 PC 2 Dataset 1 (81%) Dataset 1 (91%) Dataset 2 (62%) Dataset 2 (73%) Dataset (60%) Dataset (83%) In particular, glycemic variability indices selected by sparse principal component (PC) for each PC for datasets 1, 2, and are reported. Results change when glycemic variability indices are derived from continuous glucose monitoring time-series expressed in mmol/l (right columns) rather than in mg/dl (left columns)., Average Daily Risk Range;, Blood Glucose Risk Index;, percentage coefficient of variation;,, and, percentages of Glycemic Risk Assessment Diabetes Equation score due to euglycemia, hyperglycemia, and hypoglycemia, respectively;, High Blood Glucose Index;, Index of Glucose Control;, Low Blood Glucose Index;, Mean Amplitude of Glycemic Excursions.

CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes

CareLink. software REPORT REFERENCE GUIDE. Management Software for Diabetes CareLink Management Software for Diabetes software REPORT REFERENCE GUIDE How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used

More information

Report Reference Guide

Report Reference Guide Report Reference Guide How to use this guide Each type of CareLink report and its components are described in the following sections. Report data used to generate the sample reports was from sample patient

More information

APPENDIX American Diabetes Association. Published online at

APPENDIX American Diabetes Association. Published online at APPENDIX 1 INPATIENT MANAGEMENT OF TYPE 2 DIABETES No algorithm applies to all patients with diabetes. These guidelines apply to patients with type 2 diabetes who are not on glucocorticoids, have no

More information

Hypoglycemia Reassessment at Orange Regional Medical Center

Hypoglycemia Reassessment at Orange Regional Medical Center What is the Society of Medicine s Glycemic Control equips Program? The Society of Medicine s (SHM s) Glycemic Control Electronic Quality Improvement Program (GC equips) assists with optimizing glycemic

More information

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

THERAPY MANAGEMENT SOFTWARE FOR DIABETES THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2007 Medtronic MiniMed. All rights reserved. 6025274-0U2 120707 CareLink Pro Report Reference Guide 0 p.2 Sensor

More information

Report Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1

Report Reference Guide. THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1 Report Reference Guide THERAPY MANAGEMENT SOFTWARE FOR DIABETES CareLink Report Reference Guide 1 How to use this guide Each type of CareLink report and its components are described in the following sections.

More information

OneTouch Reveal web app Report Reference Guide

OneTouch Reveal web app Report Reference Guide OneTouch Reveal web app Report Reference Guide Your step-by-step guide to setting up and using the OneTouch Reveal web app OneTouch Verio meter OneTouch Verio Flex meter OneTouch Verio IQ meter OneTouch

More information

THERAPY MANAGEMENT SOFTWARE FOR DIABETES

THERAPY MANAGEMENT SOFTWARE FOR DIABETES THERAPY MANAGEMENT SOFTWARE FOR DIABETES Report Report Interpretation Reference Guide Guide 2009 Medtronic MiniMed. All rights reserved. 6025274-012_a CareLink Pro Report Reference Guide 0 p.2 Adherence

More information

Glycemic Variability:

Glycemic Variability: Glycemic Variability: Do the Differences Make a Difference? Kim L Kelly, PharmD, BCPS, FCCP Define Variability VERY LOW GLYCEMIC VARIABILITY LOW GLYCEMIC VARIABILITY HIGH GLYCEMIC VARIABILITY So what s

More information

Glycemic Control IU Health Diabetes Centers

Glycemic Control IU Health Diabetes Centers Glycemic Control IU Health Diabetes Centers Central Nursing Orientation 3/10/2014 1 Objectives Identify laboratory results that diagnosis diabetes and reflect glycemic control Describe glycemic control

More information

DIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL

DIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL DIABETES MANAGEMENT DISCHARGE COMMUNICATION (DM-DC) AUDIT TOOL Facility: Date: Data Collector s name: Email/Phone: Purpose: To evaluate your facility practices regarding communication of requisite diabetes

More information

April Dear (Editor):

April Dear (Editor): April 2014 Dear (Editor): Registered Dietitians (RD) play an integral role in patient care in the medical intensive care unit. RD s have increased knowledge in blood glucose control and reducing adverse

More information

Clinical Value and Evidence of Continuous Glucose Monitoring

Clinical Value and Evidence of Continuous Glucose Monitoring Clinical Value and Evidence of Continuous Glucose Monitoring 9402313-012 Objective To review the clinical value and the recent clinical evidence for Professional and Personal CGM Key Points CGM reveals

More information

GLYCEMIC CONTROL IN NEUROCRITICAL CARE PATIENTS

GLYCEMIC CONTROL IN NEUROCRITICAL CARE PATIENTS GLYCEMIC CONTROL IN NEUROCRITICAL CARE PATIENTS David Zygun MD MSc FRCPC Professor and Director Division of Critical Care Medicine University of Alberta Zone Clinical Department Head Critical Care Medicine,

More information

CSE 255 Assignment 9

CSE 255 Assignment 9 CSE 255 Assignment 9 Alexander Asplund, William Fedus September 25, 2015 1 Introduction In this paper we train a logistic regression function for two forms of link prediction among a set of 244 suspected

More information

Position Statement of ADA / EASD 2012

Position Statement of ADA / EASD 2012 Management of Hyperglycemia in Type2 Diabetes: A Patient- Centered Approach Position Statement of ADA / EASD 2012 Cause of : Type 2 diabetes Cardiovascular disorders Blindness End-stage renal failure Amputations

More information

Diabetes Care 32: , for achieving euglycemia in type 1 diabetes

Diabetes Care 32: , for achieving euglycemia in type 1 diabetes Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes JUVENILE DIABETES RESEARCH FOUNDATION

More information

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim

Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest

More information

Usefulness of Ambulatory Glucose Profile (AGP) in Diabetes Care

Usefulness of Ambulatory Glucose Profile (AGP) in Diabetes Care C H A P T E R 41 Usefulness of Ambulatory Glucose Profile (AGP) in Diabetes Care K Chaithanya Murthy, B Ramya, E Vidya, RM Anjana, V Mohan ABSTRACT Over the past decades, several newer technologies have

More information

Norbert Hermanns, PhD 1,2, Beatrix Schumann, MD 2, Bernhard Kulzer, PhD 1,2, and Thomas Haak, MD 1,2. Original Article

Norbert Hermanns, PhD 1,2, Beatrix Schumann, MD 2, Bernhard Kulzer, PhD 1,2, and Thomas Haak, MD 1,2. Original Article 524105DSTXXX10.1177/1932296814524105Journal of Diabetes Science and TechnologyHermanns et al research-article2014 Original Article The Impact of Continuous Glucose Monitoring on Low Interstitial Glucose

More information

Emanuele Bosi dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche:

Emanuele Bosi dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche: Emanuele Bosi dichiara di aver ricevuto negli ultimi due anni compensi o finanziamenti dalle seguenti Aziende Farmaceutiche e/o Diagnostiche: - Abbott - Roche - Takeda - Novartis - Astra Zeneca - Medtronic

More information

Multiplicative Surrogate Standard Deviation A Group Metric for the Glycemic Variability of Individual Hospitalized Patients

Multiplicative Surrogate Standard Deviation A Group Metric for the Glycemic Variability of Individual Hospitalized Patients Multiplicative Surrogate Standard Deviation A Group Metric for the Glycemic Variability of Individual Hospitalized Patients Susan S. Braithwaite, M.D. Visiting Clinical Professor, University of Illinois

More information

10.4.a. Optimal glucose control: Insulin therapy March 2013

10.4.a. Optimal glucose control: Insulin therapy March 2013 10.4.a. Optimal glucose control: Insulin therapy March 2013 2013 Recommendation: Based on 26 level 2 studies, we recommend that hyperglycemia (blood sugars > 10 mmol/l) be avoided in all critically ill

More information

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1

Sponsor / Company: Sanofi Drug substance(s): insulin glargine (HOE901) According to template: QSD VERSION N 4.0 (07-JUN-2012) Page 1 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

Sensor-augmented pump systems provide insulin delivery

Sensor-augmented pump systems provide insulin delivery DIABETES TECHNOLOGY & THERAPEUTICS Volume 18, Number 10, 2016 Mary Ann Liebert, Inc. DOI: 10.1089/dia.2016.0216 ORIGINAL ARTICLE Effectiveness of Automated Insulin Management Features of the MiniMed c

More information

Influence of overweight and obesity on the diabetes in the world on adult people using spatial regression

Influence of overweight and obesity on the diabetes in the world on adult people using spatial regression International Journal of Advances in Intelligent Informatics ISSN: 2442-6571 149 Influence of overweight and obesity on the diabetes in the world on adult people using spatial regression Tuti Purwaningsih

More information

Supplementary Figure 1. Blood glucose and insulin levels in mice during 4-day infusion.

Supplementary Figure 1. Blood glucose and insulin levels in mice during 4-day infusion. Supplementary Figure 1. Blood glucose and insulin levels in mice during 4-day infusion. (A-B) WT and HT mice infused with saline or glucose had overlapping achieved blood glucose and insulin levels, necessitating

More information

BAPTIST HEALTH SCHOOL OF NURSING NSG 3026A: CHILDREN S HEALTH

BAPTIST HEALTH SCHOOL OF NURSING NSG 3026A: CHILDREN S HEALTH J 1 BAPTIST HEALTH SCHOOL OF NURSING NSG 3026A: CHILDREN S HEALTH NURSING MANAGEMENT OF ENDOCRINE DYSFUNCTION: THEORETICAL SKILLS and KNOWLEDGE, SCIENTIFIC PRINCIPLES, CRITICAL THINKING, HEALTHCARE PROMOTION,

More information

REPORT INTERPRETATION

REPORT INTERPRETATION REPORT INTERPRETATION: Interpreting ipro Professional Continuous Glucose Monitoring (CGM) Reports and Making Therapy Adjustments TARGET AUDIENCE The audience for this section is physicians, mid-level practitioners,

More information

Bedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L

Bedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L Diabetes Ther (2018) 9:2155 2162 https://doi.org/10.1007/s13300-018-0507-0 BRIEF REPORT Bedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L Ariel Zisman.

More information

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded

nocturnal hypoglycemia percentage of Hispanics in the insulin glargine than NPH during forced patients who previously This study excluded Clinical Trial Design/ Primary Objective Insulin glargine Treat-to-Target Trial, Riddle et al., 2003 (23) AT.LANTUS trial, Davies et al., 2005 (24) INSIGHT trial, Gerstein et al., 2006 (25) multicenter,

More information

The next five years in diabetes technology: closed-loop systems

The next five years in diabetes technology: closed-loop systems The next five years in diabetes technology: closed-loop systems J. H. (Hans) DeVries Academic Medical Center at the University of Amsterd, the Netherlands Keystone, CO, 19 July 2013 Disclosure AP@home,

More information

Journal Club ICU

Journal Club ICU Journal Club 2018.9.4 ICU Crit Care Med. 2018 Aug;46(8):1224-1229 Introduction Stress hyperglycemia SH SH >124 mg/dl or >200 mg/dl Lancet 2009;373:1798. stress hyperglycemia Lancet 2009;373:1798. SH Critical

More information

Lessons Learned: Interdisciplinary collaboration to reduce hypoglycemic events

Lessons Learned: Interdisciplinary collaboration to reduce hypoglycemic events Lessons Learned: Interdisciplinary collaboration to reduce hypoglycemic events Ryan ull, Pharm.., BCPS ssistant Professor of Pharmacy Practice Creighton niversity School of Pharmacy legent Health Lakeside

More information

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Objectives u At conclusion of the lecture the participant will be able to: 1. Differentiate between the classifications of diabetes

More information

Supplementary Data. Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles Z T 1 T

Supplementary Data. Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles Z T 1 T Supplementary Data Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles 1 T Z T O jig(t) IGjdt IG, interstitial glucose; IG(t), IG value at time t; IG, mean IG from the

More information

6/10/2016. Hui-Chun Hsu

6/10/2016. Hui-Chun Hsu Hui-Chun Hsu PhD, RN, CDE Chief, Department of Diabetes Management Lee s Endocrinology Clinic Pingtung, Taiwan Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures:

More information

Q99: At what plasma glucose level would glycosuria be expected? Q101: What is the cause of polydipsia in the hypoglycemia?

Q99: At what plasma glucose level would glycosuria be expected? Q101: What is the cause of polydipsia in the hypoglycemia? Q99: At what plasma glucose level would glycosuria be expected? Q100: What is the cause of polyemia in hyperglycemia? Q101: What is the cause of polydipsia in the hypoglycemia? Q102: What is the effect

More information

A toolbox to improve algorithms for insulin-dosing decision support

A toolbox to improve algorithms for insulin-dosing decision support 548 A toolbox to improve algorithms for insulin-dosing decision support K. Donsa 1 ; P. Beck 1 ; J. Plank 2 ; L. Schaupp 2 ; J. K. Mader 2 ; T. Truskaller 1 ; B. Tschapeller 1 ; B. Höll 1 ; S. Spat 1 ;

More information

Chapter 37: Exercise Prescription in Patients with Diabetes

Chapter 37: Exercise Prescription in Patients with Diabetes Chapter 37: Exercise Prescription in Patients with Diabetes American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:

More information

Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier??

Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Hypoglycemia a barrier to normoglycemia Are long acting analogues and pumps the answer to the barrier?? Moshe Phillip Institute of Endocrinology and Diabetes National Center of Childhood Diabetes Schneider

More information

Non-insulin treatment in Type 1 DM Sang Yong Kim

Non-insulin treatment in Type 1 DM Sang Yong Kim Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay

More information

OneTouch Reveal Web Application. User Manual for Healthcare Professionals Instructions for Use

OneTouch Reveal Web Application. User Manual for Healthcare Professionals Instructions for Use OneTouch Reveal Web Application User Manual for Healthcare Professionals Instructions for Use Contents 2 Contents Chapter 1: Introduction...4 Product Overview...4 Intended Use...4 System Requirements...

More information

ESPEN Congress Madrid 2018

ESPEN Congress Madrid 2018 ESPEN Congress Madrid 2018 Dysglycaemia In Acute Patients With Nutritional Therapy Mechanisms And Consequences Of Dysglycaemia In Patients Receiving Nutritional Therapy M. León- Sanz (ES) Mechanisms and

More information

Deepika Reddy MD Department of Endocrinology

Deepika Reddy MD Department of Endocrinology Deepika Reddy MD Department of Endocrinology Management of hyperglycemic crisis Review need for inpatient glycemic control Brief overview of relevant trials Case based review of diabetes management strategies/review

More information

Goals & Objectives. Diabetes Mellitus

Goals & Objectives. Diabetes Mellitus Rudy R. Navarro, M.D., CAQSM Department of Family & Community Medicine UT Health Science Center at San Antonio Goals & Objectives Understand the patterns of glucose utilization during exercise and sporting

More information

Continuous Glucose Monitoring (CGM)

Continuous Glucose Monitoring (CGM) Continuous Glucose Monitoring (CGM) Background Info A1c Average glucose levels over previous 2-3 months Currently remains gold standard for determining control Indicator of risk for development of complications

More information

Discrete Mean Amplitude of Glycemic Excursion (MAGE) Measurement on Diabetics with Spline Interpolation Method

Discrete Mean Amplitude of Glycemic Excursion (MAGE) Measurement on Diabetics with Spline Interpolation Method International Journal on Electrical Engineering and Informatics - Volume 10, Number 2, June 2018 Discrete Mean Amplitude of Glycemic Excursion (MAGE) Measurement on Diabetics with Spline Interpolation

More information

bivariate analysis: The statistical analysis of the relationship between two variables.

bivariate analysis: The statistical analysis of the relationship between two variables. bivariate analysis: The statistical analysis of the relationship between two variables. cell frequency: The number of cases in a cell of a cross-tabulation (contingency table). chi-square (χ 2 ) test for

More information

PREVALENCE AND EXTENT OF GLYCEMIC EXCURSIONS IN WELL- CONTROLLED PATIENTS WITH TYPE 2 DIABETES MELLITUS USING CONTINUOUS GLUCOSE-MONITORING SYSTEM

PREVALENCE AND EXTENT OF GLYCEMIC EXCURSIONS IN WELL- CONTROLLED PATIENTS WITH TYPE 2 DIABETES MELLITUS USING CONTINUOUS GLUCOSE-MONITORING SYSTEM 66 PREVALENCE AND EXTENT OF GLYCEMIC EXCURSIONS IN WELL- CONTROLLED PATIENTS WITH TYPE 2 DIABETES MELLITUS USING CONTINUOUS GLUCOSE-MONITORING SYSTEM SHOKOUFEH BONAKDARAN, REZA RAJABIAN ABSTRACT BACKGROUND:

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)

More information

Simone Del Favero, PhD, Andrea Facchinetti, PhD, Giovanni Sparacino, PhD, and Claudio Cobelli, PhD

Simone Del Favero, PhD, Andrea Facchinetti, PhD, Giovanni Sparacino, PhD, and Claudio Cobelli, PhD DIA-2016-0413-ver9-Favero_3P.3d 03//17 12:40pm Page 1 DIABETES TECHNOLOGY & THERAPEUTICS Volume 19, Number 4, 2017 ª Mary Ann Liebert, Inc. DOI:.89/dia.2016.0413 ORIGINAL ARTICLE Retrofitting Real-Life

More information

Is Intense Glycemic Control Really Better?

Is Intense Glycemic Control Really Better? University of Wyoming Wyoming Scholars Repository Honors Theses AY 16/17 Undergraduate Honors Theses Spring 5-12-2017 Is Intense Glycemic Control Really Better? Cierra W. Schutzman University of Wyoming,

More information

Ensuring Safe Physical Activity in Children and Adolescents With Type 1 Diabetes

Ensuring Safe Physical Activity in Children and Adolescents With Type 1 Diabetes Ensuring Safe Physical Activity in Children and Adolescents With Type 1 Diabetes FACULTY ADVISOR Lori Laffel, MD, MPH Professor, Pediatrics Harvard Medical School Chief, Pediatric, Adolescent and Young

More information

Estimation of Blood Glucose level. Friday, March 7, 14

Estimation of Blood Glucose level. Friday, March 7, 14 Estimation of Blood Glucose level Importance Diagnosis and treatment of carbohydrate metabolism disorders Monitor the effectivity and response to an ongoing treatment procedure Control mechanism Insulin

More information

Structured Association Advanced Topics in Computa8onal Genomics

Structured Association Advanced Topics in Computa8onal Genomics Structured Association 02-715 Advanced Topics in Computa8onal Genomics Structured Association Lasso ACGTTTTACTGTACAATT Gflasso (Kim & Xing, 2009) ACGTTTTACTGTACAATT Greater power Fewer false posi2ves Phenome

More information

Correct Site Rotation

Correct Site Rotation Injection Techniques Questionnaire (ITQ) WorldWide Results 2014-2015 Correct Site Rotation BACKGROUND Correct Rotation = at least 1 cm between successive injections Lipohypertrophy and Observed Correct

More information

CARBOHYDRATE METABOLISM Disorders

CARBOHYDRATE METABOLISM Disorders CARBOHYDRATE METABOLISM Disorders molecular formula C12H22O11 Major index which describes metabolism of carbohydrates, is a sugar level in blood. In healthy people it is 4,4-6,6 mmol/l (70-110 mg/dl)

More information

Welcome to CareLink Pro

Welcome to CareLink Pro Reference Guide Welcome to CareLink Pro This guide was developed to serve as a reference for obtaining patient data and reviewing CareLink Pro reports. Getting Started with CareLink Pro Adding New Patients

More information

Parameter Estimation of Cognitive Attributes using the Crossed Random- Effects Linear Logistic Test Model with PROC GLIMMIX

Parameter Estimation of Cognitive Attributes using the Crossed Random- Effects Linear Logistic Test Model with PROC GLIMMIX Paper 1766-2014 Parameter Estimation of Cognitive Attributes using the Crossed Random- Effects Linear Logistic Test Model with PROC GLIMMIX ABSTRACT Chunhua Cao, Yan Wang, Yi-Hsin Chen, Isaac Y. Li University

More information

The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections

The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections 8/5/217 The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections Richard M. Bergenstal, MD Executive Director International Diabetes Center at Park Nicollet Minneapolis,

More information

Insulin Initiation and Intensification. Disclosure. Objectives

Insulin Initiation and Intensification. Disclosure. Objectives Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-loop insulin

More information

Diabetes Mellitus Type 2 Evidence-Based Drivers

Diabetes Mellitus Type 2 Evidence-Based Drivers This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose

More information

Physical Activity/Exercise Prescription with Diabetes

Physical Activity/Exercise Prescription with Diabetes Physical Activity/Exercise Prescription with Diabetes B R AD H I NTERMEYER C E P A C SM S A NFORD H E ALTH C A RDIAC R E H AB A N D D I ABE TES E XE RCISE The adoption and maintenance of physical activity

More information

Normal glucose values are associated with a lower risk of mortality in hospitalized patients

Normal glucose values are associated with a lower risk of mortality in hospitalized patients Diabetes Care Publish Ahead of Print, published online August Hyperglycemia 20, 2008 in hospital Normal glucose values are associated with a lower risk of mortality in hospitalized patients Alberto Bruno

More information

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic Supplementary Information The title of the manuscript Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke Xin-Wei He 1, Wei-Ling Li 1, Cai Li

More information

Insulin Prior Authorization with optional Quantity Limit Program Summary

Insulin Prior Authorization with optional Quantity Limit Program Summary Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)

More information

International Journal on Future Revolution in Computer Science & Communication Engineering ISSN: Volume: 4 Issue:

International Journal on Future Revolution in Computer Science & Communication Engineering ISSN: Volume: 4 Issue: Application of the Variance Function of the Difference Between two estimated responses in regulating Blood Sugar Level in a Diabetic patient using Herbal Formula Karanjah Anthony N. School of Science Maasai

More information

4.2a Composition of Enteral Nutrition: (Carbohydrate/fat): High fat/low CHO March 2013

4.2a Composition of Enteral Nutrition: (Carbohydrate/fat): High fat/low CHO March 2013 4.2a Composition of Enteral Nutrition: (Carbohydrate/fat): March 203 There were no new randomized controlled trials since the 2009 update and hence there are no changes to the following Summary of Evidence.

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Baidal DA, Ricordi C, Berman DM, et al. Bioengineering of an

More information

Hyperglycemia Procedure: Management and Treatment Adult Patients

Hyperglycemia Procedure: Management and Treatment Adult Patients Approved by: Chief Operating Officer; and Chief Medical Officer Hyperglycemia Procedure: Management and Treatment Corporate Policy & Procedures Manual Number: VII-B-465 Date Approved January 23, 2018 Date

More information

Appendix 3: Definition of the types of missingness and terminology used by each paper to

Appendix 3: Definition of the types of missingness and terminology used by each paper to Appendix 3: Definition of the types of missingness and terminology used by each paper to describe the different reasons for missing participant data, with specific terms underlined. Definitions Missing

More information

GLUCOSE CONTROL IN TYPE I DIABETIC PATIENTS: A VOLTERRA MODEL BASED APPROACH. Justin D. Rubb and Robert S. Parker

GLUCOSE CONTROL IN TYPE I DIABETIC PATIENTS: A VOLTERRA MODEL BASED APPROACH. Justin D. Rubb and Robert S. Parker GLUCOSE CONTROL IN TYPE I DIABETIC PATIENTS: A VOLTERRA MODEL BASED APPROACH Justin D. Rubb and Robert S. Parker Department of Chemical and Petroleum Engineering University of Pittsburgh Pittsburgh, PA

More information

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section.

NOTE: The first appearance of terms in bold in the body of this document (except titles) are defined terms please refer to the Definitions section. TITLE TREATMENT OF HYPERGLYCEMIA - ADULT SCOPE Provincial: Acute Care APPROVAL AUTHORITY Clinical Operations Executive Committee SPONSOR Diabetes, Obesity & Nutrition Strategic Clinical Network PARENT

More information

Diabetes Care 34: , 2011

Diabetes Care 34: , 2011 Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Use of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes on Multiple Daily Injections Versus Continuous

More information

Diabetes Mellitus in Older Adults. Presenter Disclosure Information

Diabetes Mellitus in Older Adults. Presenter Disclosure Information Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from

More information

VIRTUAL PATIENTS DERIVED FROM THE

VIRTUAL PATIENTS DERIVED FROM THE VIRTUAL PATIENTS DERIVED FROM THE CARELINK DATABASE Benyamin Grosman PhD Senior Principle Scientist Medtronic Diabetes WHY VIRTUAL PATIENT MODELING? Reduce the cost of clinical trials Use models in conjunction

More information

EmergencyKT: New Onset Diabetes, Non-DKA Definition: ED patient with newly discovered hyperglycemia, >200 mg %

EmergencyKT: New Onset Diabetes, Non-DKA Definition: ED patient with newly discovered hyperglycemia, >200 mg % EmergencyKT: New Onset, Non-DKA Definition: ED patient with newly discovered hyperglycemia, >200 mg % Obtain: CBCD EP1 VBG Serum Ketone Hemoglobin A1c (for follow up) UA β-hcg (female at risk for pregnancy)

More information

Diabetic Equipment and Supplies

Diabetic Equipment and Supplies Diabetic Equipment and Supplies Chapter.1 Enrollment..................................................................... -2.2 Benefits, Limitations, and Authorization Requirements...........................

More information

Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis

Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis Diabetes Ther (2018) 9:1995 2014 https://doi.org/10.1007/s13300-018-0493-2 ORIGINAL RESEARCH Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic

More information

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items

Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Diabetes Update: Intensifying Insulin Therapy Nuts, Bolts and Other Items Hayley A. Miller, MD Physician, Internal Medicine, Diabetes and Metabolism, Sandy Clinic, Intermountain Healthcare Objectives:

More information

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia

More information

Continuous Glucose Monitoring System

Continuous Glucose Monitoring System Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/01/2016 Section: DME Place(s)

More information

Clinical Study Glycemic Profiles of Healthy Individuals with Low Fasting Plasma Glucose and HbA1c

Clinical Study Glycemic Profiles of Healthy Individuals with Low Fasting Plasma Glucose and HbA1c International Scholarly Research Network ISRN Endocrinology Volume 2011, Article ID 435047, 6 pages doi:10.5402/2011/435047 Clinical Study Glycemic Profiles of Healthy Individuals with Low Fasting Plasma

More information

Acute Glycemic Changes in Brain and Subcutaneous Tissue Measured by Continuous Glucose Monitoring System in Hereditary Hypertriglyceridemic Rat

Acute Glycemic Changes in Brain and Subcutaneous Tissue Measured by Continuous Glucose Monitoring System in Hereditary Hypertriglyceridemic Rat Physiol. Res. 67: 127-131, 2018 Acute Glycemic Changes in Brain and Subcutaneous Tissue Measured by Continuous Glucose Monitoring System in Hereditary Hypertriglyceridemic Rat M. ŽOUREK 1, P. KYSELOVÁ

More information

Alarge, randomized, controlled trial

Alarge, randomized, controlled trial Emerging Treatments and Technologies O R I G I N A L A R T I C L E Glucommander A computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation PAUL C.

More information

Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. November 12, 2016

Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. November 12, 2016 Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events November 12, 2016 St Joseph s Health Fast Facts Founded 1869 by Sisters of St. Francis Patient Volumes (2014) Inpatient

More information

Biochemistry. ENDOCRINE Block Practical Sessions. Editing file M E D I C I N E

Biochemistry. ENDOCRINE Block Practical Sessions. Editing file M E D I C I N E HbA NH 2 H 2 O 2 KClO 3 Cl 2 O 7 PO 4 CH2O NAOH KMnO 4 M E D I C I N E KING SAUD UNIVERSITY Co 2 COOH MgCl 2 H 2 O Biochemistry ENDOCRINE Block Practical Sessions Important Doctors slides Extra Information

More information

VANDERBILT UNIVERSITY MEDICAL CENTER MULTIDISCIPLINARY SURGICAL CRITICAL CARE TRAUMA INTENSIVE CARE UNIT GLYCEMIC CONTROL PROTOCOL

VANDERBILT UNIVERSITY MEDICAL CENTER MULTIDISCIPLINARY SURGICAL CRITICAL CARE TRAUMA INTENSIVE CARE UNIT GLYCEMIC CONTROL PROTOCOL VANDERBILT UNIVERSITY MEDICAL CENTER MULTIDISCIPLINARY SURGICAL CRITICAL CARE TRAUMA INTENSIVE CARE UNIT GLYCEMIC CONTROL PROTOCOL Background: For some time, the presence of diabetes and hyperglycemia

More information

Continuous Glucose Monitoring System

Continuous Glucose Monitoring System Continuous Glucose Monitoring System Policy Number: Original Effective Date: MM.02.003 03/13/2001 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 4/1/2018 Section: DME Place(s)

More information

GLYCEMIC CONTROL SURVEY

GLYCEMIC CONTROL SURVEY GLYCEMIC CONTROL SURVEY Objective: To gain an understanding of the current state of glycemic control (ie, intensive insulin therapy and frequent blood glucose testing) protocol use in hospital inpatients.

More information

Received for publication 20 October 2006 and accepted in revised form 15 April 2007.

Received for publication 20 October 2006 and accepted in revised form 15 April 2007. Diabetes Care In Press, published online April 27, 2007 1 Outpatient assessment of KADIS based decision support Received for publication 20 October 2006 and accepted in revised form 15 April 2007. Petra

More information

Tuberculosis and Diabetes

Tuberculosis and Diabetes Tuberculosis and Diabetes National Web-based Seminar Francis J. Curry National TB Center San Francisco, California December 1, 29 Jane Kelly, M.D. Centers for Disease Control and Prevention jkelly@cdc.gov

More information

Hyperglycemia in ACS. Dr. Imhemed Eljazwi

Hyperglycemia in ACS. Dr. Imhemed Eljazwi Hyperglycemia in ACS 2012-5-8 Dr. Imhemed Eljazwi Percentage of Population (n = 1181) Prevalence of Hyperglycemia in 181 Cardiac Patients Without Known Diabetes 100% 75% 50% 66% of AMI patients have

More information

Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. September 13, 2016

Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events. September 13, 2016 Implementation of an Interprofessional Team to Prevent Inpatient Hypoglycemic Events September 13, 2016 St Joseph s Health Fast Facts Founded 1869 by Sisters of St. Francis Patient Volumes (2014) Inpatient

More information

Development of Optimal Kids Insulin Dosing System Formulas for Young Children with Type 1 Diabetes Mellitus

Development of Optimal Kids Insulin Dosing System Formulas for Young Children with Type 1 Diabetes Mellitus DIABETES TECHNOLOGY & THERAPEUTICS Volume 14, Number 5, 2012 ª Mary Ann Liebert, Inc. DOI: 10.1089/dia.2011.0184 Development of Optimal Kids Insulin Dosing System Formulas for Young Children with Type

More information

Inpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy

Inpatient Management of Diabetes Mellitus. Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy Inpatient Management of Diabetes Mellitus Jessica Garza, Pharm.D. PGY-1 Pharmacotherapy Resident TTUHSC School of Pharmacy 2 Disclosure Jessica Garza does not have any actual or potential conflicts of

More information

CONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario. Antonio Ceriello a,b

CONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario. Antonio Ceriello a,b CONTROLLO GLICEMICO NEL PAZIENTE CON DMT2: E' SUFFICIENTE HbA1C? Contrario Antonio Ceriello a,b Excessive Glucose Fluctuations With Same A1C Values 400 Mean A1C = 6.7% Glucose Concentration (mg/dl) 300

More information